RIO DE JANEIRO, BRAZIL - Sinovac Biotech announced Wednesday, June 30, that its Covid-19 vaccine Coronavac - manufactured in Brazil by Instituto Butantan - is safe in children 3 years of age and older and also elicits a strong immune response in 96% of participants.
The combined Phase 1 and Phase 2 trial, which used a randomized double-blind design, enrolled 552 young volunteers aged 3 years and older, with two doses given 28 days apart.
The Chinese pharmaceutical company's test results were published in the journal The Lancet Infectious Diseases.
China previously granted emergency approval of the vaccine for the . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here